Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study

NCT03161353 is registered in ClinicalTrials.gov with MedSIR as lead sponsor.

NCT NCT03161353
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03161353 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive (Human Epidermal Receptor) Breast Cancer: FDG-PET Response-adapted Strategy. The PHERGain Study
Lead sponsor
MedSIR
Phase
Phase 2
Overall status
Active, not recruiting
Start date
June 26, 2017
Completion date
November 1, 2026
Enrollment
377 (actual)
Sites
56

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer